Short Bowel Syndrome

1. Overview
2. Causes and Anatomy of Loss
3. Anatomical Types and Severity
4. Pathophysiology: Losses and Hypergastrinemia
5. Intestinal Adaptation
6. Nutritional Management and Parenteral Nutrition
7. Medications
8. Teduglutide (GLP-2 Analogue)
9. Surgical Options
10. Research Papers
11. Connections
12. Featured Videos

Overview

Short bowel syndrome (SBS) is a state of chronic intestinal failure arising from massive loss of functional small bowel, leaving insufficient absorptive surface to maintain adequate fluid, electrolyte, macronutrient, and micronutrient balance without medical support.

The diagnostic threshold is generally a small bowel remnant of less than 200 cm (normal adult small bowel length is 600–800 cm). However, functional severity depends not only on remnant length but critically on which segment remains, whether the colon is in continuity, and whether the ileocecal valve has been preserved.

SBS may require long-term or permanent parenteral nutrition (PN) — the most complex and costly form of nutritional support, and one that carries significant long-term complications including catheter-related bloodstream infections, PN-associated liver disease, and metabolic bone disease.

↑ Back to Table of Contents

Causes and Anatomy of Loss

Three major mechanisms account for the vast majority of adult SBS:

Crohn's Disease (most common adult cause)

• Repeated surgical resections over years → cumulative bowel loss
• Terminal ileum (most commonly affected segment in Crohn's) has critical functions: B12 absorption, bile acid reabsorption, ileal brake hormone (GLP-1, PYY) secretion
• Crohn's-related SBS is typically gradual and somewhat predictable

Mesenteric Ischemia / Volvulus / Trauma

• Acute total or near-total small bowel loss in a single catastrophic event
• Superior mesenteric artery (SMA) occlusion → massive ischemia
• Midgut volvulus (more common in neonates/children)
• Abdominal trauma with vascular injury

Radiation Enteritis

• Late complication of pelvic/abdominal radiation (cervical, prostate, rectal cancers)
• Progressive fibrosis + endarteritis → malabsorption + strictures
• Bowel resection of irradiated segments → SBS

Less common causes: necrotizing enterocolitis (neonates/premature infants), adhesion-related volvulus, tumors, bypass surgery complications.

↑ Back to Table of Contents

Anatomical Types and Severity

The remaining anatomy after intestinal loss defines three functional SBS types:

Type 1 — End-Jejunostomy (most severe)

• No colon in continuity; entire ileum + colon removed
• Massive, high-output fluid + electrolyte losses (3–6 L/day stomal output)
• Dependent on long-term PN; most difficult to wean
• Bile acid reabsorption completely abolished → fat malabsorption + deficiency of fat-soluble vitamins (A, D, E, K)
• Remnant jejunum >100 cm offers more adaptation potential than <100 cm

Type 2 — Jejuno-Colonic Anastomosis (moderate)

• Ileum removed but colon intact (absorbs some fluid/electrolytes + short-chain fatty acids from bacterial fermentation)
• Colon provides significant energy salvage via fermentation of malabsorbed carbohydrates
• Diarrhea less severe than Type 1, but D-lactic acidosis risk (bacterial overgrowth + excess carbohydrate fermentation)
• Bile acid malabsorption → cholerheic diarrhea + oxalate hyperabsorption → calcium oxalate kidney stones

Type 3 — Jejuno-Ileal Anastomosis (mildest)

• Both ileum preserved (or portion) + colon retained
• Ileocecal valve preservation reduces bacterial overgrowth + slows transit
• Best functional prognosis; some patients wean PN fully

↑ Back to Table of Contents

Pathophysiology: Losses and Hypergastrinemia

Fluid and Electrolyte Losses

• Normal: jejunum absorbs 5–6 L/day; terminal ileum absorbs bile acids + Na/Cl; colon salvages 1–2 L/day
• SBS: net secretion can exceed intake — jejunum becomes net secretor below certain luminal sodium concentrations (oral rehydration solution must be >90 mEq/L Na to drive absorption rather than secretion)
• Stomal output monitoring and sodium replacement are central to management

Hypergastrinemia

• Loss of ileum removes enteric feedback inhibition on gastric acid secretion
• Massive acid hypersecretion in acute SBS → peptic ulceration + deactivation of pancreatic enzymes
• PPIs essential in early SBS management (may be weaned as adaptation proceeds)

Small Intestinal Bacterial Overgrowth (SIBO)

• Common in SBS, especially without ileocecal valve
• Contributes to D-lactic acidosis, bloating, diarrhea, nutritional deficiency
• Treated with antibiotic cycling (rifaximin, metronidazole, ciprofloxacin)

Oxalate Nephropathy (Type 2 SBS with colon in continuity)

• Malabsorbed fat binds luminal calcium → free oxalate absorbed by colon → calcium oxalate urolithiasis
• Low-oxalate diet + calcium supplementation with meals essential

↑ Back to Table of Contents

Intestinal Adaptation

Intestinal adaptation is the process by which the remnant bowel increases absorptive capacity over time — the biological rationale for aggressive enteral feeding from the earliest safe opportunity:

Timing: begins within days of resection; most adaptation occurs in the first 1–2 years.

Structural Changes

• Villous hyperplasia (increased villous height, crypt depth, mucosal surface area)
• Bowel wall dilation + elongation
• Upregulation of nutrient transporters (SGLT-1, GLUT-5, DPPIV)

Drivers of Adaptation

• Enteral nutrients (essential — luminal stimulation drives adaptation; PN alone does not)
• GLP-2 (glucagon-like peptide 2, secreted by L-cells in ileum/colon) — intestinotrophic hormone; basis for teduglutide therapy
• Epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1)
• Bile acids (luminal trophic effect)

Clinical implication: introduce enteral feeding (oral or tube) as early as the surgical team permits — even minimal enteral intake drives adaptation faster than PN alone.

↑ Back to Table of Contents

Nutritional Management and Parenteral Nutrition

Phase 1 — Acute (0–3 months, high fluid/electrolyte losses)

• Parenteral nutrition provides life-sustaining calories, protein, vitamins, minerals
• Meticulous fluid/electrolyte balance (Na, K, Mg, Ca, Zn replace losses)
• Oral intake gradually introduced: small, frequent, isotonic, salty meals
• Oral rehydration solutions with >90 mEq/L sodium (not standard sports drinks, which are too low in Na)

Phase 2 — Adaptation (3–12+ months)

• Gradual increase in enteral/oral intake
• PN weaned as enteral intake improves — intestinal function monitored by urine output + electrolytes
• High-complex-carbohydrate, low-fat diet preferred for colon-in-continuity patients (maximizes fermentable substrate for colonic energy salvage)
• Type 1 (end-jejunostomy): high-fat diet better tolerated (fat slows gastric emptying and reduces stomal output)

Micronutrient Monitoring (all SBS patients)

• B12 (ileum critical for absorption — monthly IM injection if ileum removed)
• Fat-soluble vitamins (A, D, E, K) — supplementation and monitoring
• Zinc, magnesium, selenium (high stomal losses)
• Iron (supplementation + monitoring)
• Essential fatty acids

PN-Associated Complications

• Central line infections (CLABSI) — preventable with sterile technique + ethanol lock protocols
• PN-associated liver disease (PNALD/IFALD) — driven by manganese toxicity, phytosterols in lipid emulsions; omega-3 lipid emulsions (SMOF) reduce PNALD
• Metabolic bone disease (osteoporosis) from Ca/vitamin D losses
• Cholelithiasis (lack of enteral stimulation reduces bile flow)

↑ Back to Table of Contents

Medications

Antidiarrheals (reduce intestinal transit + stomal output)

• Loperamide (first-line; 4 mg up to 4×/day — taken 30–60 min before meals for maximal effect)
• Diphenoxylate/atropine (alternative)
• Codeine (more potent; addiction risk)
• Cholestyramine (only in jejuno-colonic SBS — binds malabsorbed bile acids; avoid in end-jejunostomy — depletes bile acid pool)

Antisecretory

• PPIs: pantoprazole IV initially → oral — essential for hypergastrinemia (reduce acid-peptic complications + volume losses)
• Octreotide (somatostatin analogue): reduces ileostomy/stomal output by 50–80%; use cautiously long-term (cholelithiasis risk); used when other measures insufficient

↑ Back to Table of Contents

Teduglutide (GLP-2 Analogue)

Teduglutide (Gattex/Revestive) is a recombinant GLP-2 analogue approved in 2012 (FDA) for adult SBS patients dependent on parenteral support.

Mechanism

• GLP-2 receptor agonism → intestinotrophic effect (increases villous height, crypt depth, mucosal blood flow)
• Reduces gastric emptying + gastric acid secretion
• Increases intestinal absorptive capacity

Clinical Evidence

• STEPS trial (NCT00798967): 63% of teduglutide patients achieved ≥20% reduction in PN volume vs. 30% placebo; mean reduction 4.4 L/week.
• STEPS-2 (24-month extension): sustained benefit; 22% of patients fully weaned from PN.
• STEPS-3: pediatric indication confirmed, leading to 2019 FDA pediatric approval.

Dosing: 0.05 mg/kg/day subcutaneous injection.

Monitoring: colonoscopy/sigmoidoscopy at baseline and yearly (GLP-2 is intestinotrophic — theoretical polyp/tumor growth potential requires surveillance). Check for colorectal polyps before starting.

Contraindications: active or suspected GI malignancy.

↑ Back to Table of Contents

Surgical Options

Serial Transverse Enteroplasty (STEP Procedure)

• Lengthens and tapers a dilated bowel segment using linear staplers in alternating transverse applications
• Increases functional surface area + slows transit
• Best for patients with dilated remnant bowel ≥40 cm
• Can allow PN weaning in 30–50% of carefully selected patients
• Can be repeated if bowel re-dilates

Intestinal Lengthening and Tapering (Bianchi Procedure)

Alternative bowel-lengthening operation; now largely replaced by STEP in most centers.

Intestinal Transplantation

• Last resort for patients with irreversible intestinal failure + life-threatening PN complications
• Indications: recurrent line sepsis, IFALD (intestinal failure-associated liver disease), loss of venous access
• Combined liver-intestine transplant if IFALD is irreversible
• 5-year graft survival ~50%; immunosuppression complications significant
• Multidisciplinary intestinal rehabilitation programs delay/avoid transplantation in many patients

↑ Back to Table of Contents

Research Papers

1. Jeppesen PB et al. "Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure." Gastroenterology. 2012;143(6):1473–1481. PMID: 22982183
2. O'Keefe SJ et al. "Short bowel syndrome and intestinal failure: consensus definitions and overview." Clin Gastroenterol Hepatol. 2006;4(1):6–10. PMID: 16431298
3. Pironi L et al. "ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults." Clin Nutr. 2015;34(2):171–180. PMID: 25241289
4. Tappenden KA. "Intestinal adaptation following resection." JPEN J Parenter Enteral Nutr. 2014;38(1 Suppl):23S–31S. PMID: 24500929
5. Wales PW et al. "Serial transverse enteroplasty (STEP): a novel bowel lengthening procedure." J Pediatr Surg. 2003;38(3):425–429. PMID: 12632361
6. Buchman AL et al. "AGA technical review on short bowel syndrome and intestinal transplantation." Gastroenterology. 2003;124(4):1111–1134. PMID: 12671904
7. Messing B et al. "Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome." Gastroenterology. 1999;117(5):1043–1050. PMID: 10528003
8. Joly F et al. "Tube feeding improves intestinal absorption in short bowel syndrome patients." Gastroenterology. 2009;136(3):824–831. PMID: 19116143
9. Nightingale JM and Woodward JM. "Guidelines for management of patients with a short bowel." Gut. 2006;55(Suppl 4):iv1–12. PMID: 16837772
10. Scolapio JS. "Short bowel syndrome." Curr Opin Clin Nutr Metab Care. 2004;7(4):403–409. PMID: 15192444
11. Koffeman GI et al. "Classification, epidemiology and aetiology." Best Pract Res Clin Gastroenterol. 2003;17(6):879–893. PMID: 14642860
12. Westin L et al. "Teduglutide for treatment of adults with parenteral support-dependent short-bowel syndrome." Cochrane Database Syst Rev. 2020;1(1):CD012465. PMID: 31978268

↑ Back to Table of Contents

Connections

• Gastroenterology Hub
• Crohn's Disease
• SIBO
• Celiac Disease
• Ulcerative Colitis
• Glutamine
• Vitamin B12
• Zinc

↑ Back to Table of Contents

Featured Videos

Featured videos will be added shortly.